Inventor
ROTTENSTEINER HANSPETER
AT35 patents
⚠️ This page may combine multiple inventors who share the name “ROTTENSTEINER HANSPETER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BAXALTA INC
13 patentsUS9731024B2Aug 15, 2017
Nucleophilic catalysts for oxime linkage
BAXALTA INC9 citations84
US10209263B2Feb 19, 2019
Methods of measuring adamts 13 activity
BAXALTA INC5 citations83
US9492555B2Nov 15, 2016
Nucleophilic catalysts for oxime linkage
BAXALTA INC7 citations83
US9488651B2Nov 8, 2016
Methods of measuring ADAMTS 13 activity
BAXALTA INC3 citations83
US10414793B2Sep 17, 2019
Nucleophilic catalysts for oxime linkage
BAXALTA INC4 citations82
US10189888B2Jan 29, 2019
Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
BAXALTA INC6 citations81
US10576160B2Mar 3, 2020
Nucleophilic catalysts for oxime linkage
BAXALTA INC3 citations73
US10350301B2Jul 16, 2019
Blood coagulation protein conjugates
BAXALTA INC4 citations73
US10842853B2Nov 24, 2020
Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia B
BAXALTA INC2 citations70
US10189889B2Jan 29, 2019
Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
BAXALTA INC2 citations70
US11040109B2Jun 22, 2021
Blood coagulation protein conjugates
BAXALTA INC1 citations62
US9611467B2Apr 4, 2017
Subcutaneous administration of ADAMTS13
BAXALTA INC1 citations57
US10413600B2Sep 17, 2019
Subcutaneous administration of ADAMTS13
BAXALTA INC0 citations46
TAKEDA PHARMACEUTICALS CO
11 patentsUS11707536B2Jul 25, 2023
Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
TAKEDA PHARMACEUTICALS CO0 citations62
US11564992B2Jan 31, 2023
Nucleophilic catalysts for oxime linkage
TAKEDA PHARMACEUTICALS CO0 citations62
US11596671B2Mar 7, 2023
Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression
TAKEDA PHARMACEUTICALS CO0 citations60
US11492388B2Nov 8, 2022
Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
TAKEDA PHARMACEUTICALS CO0 citations60
US11254731B2Feb 22, 2022
Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
TAKEDA PHARMACEUTICALS CO0 citations60
US11999798B2Jun 4, 2024
Anti-factor IX padua antibodies
TAKEDA PHARMACEUTICALS CO0 citations58
US11098132B2Aug 24, 2021
Anti-factor IX Padua antibodies
TAKEDA PHARMACEUTICALS CO0 citations58
US12516083B2Jan 6, 2026
Nucleophilic catalysts for oxime linkage
TAKEDA PHARMACEUTICALS CO0 citations57
US11779635B2Oct 10, 2023
Subcutaneous administration of ADAMTS13
TAKEDA PHARMACEUTICALS CO0 citations56
US11185575B2Nov 30, 2021
Subcutaneous administration of ADAMTS13
TAKEDA PHARMACEUTICALS CO0 citations55
US12091675B2Sep 17, 2024
Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
TAKEDA PHARMACEUTICALS CO0 citations44
SIEKMANN JUERGEN
4 patentsUS8809501B2Aug 19, 2014
Nucleophilic catalysts for oxime linkage
SIEKMANN JUERGEN7 citations83
US8637640B2Jan 28, 2014
Blood coagulation protein conjugates
SIEKMANN JUERGEN9 citations83
US8642737B2Feb 4, 2014
Nucleophilic catalysts for oxime linkage
SIEKMANN JUERGEN12 citations81
US8945897B2Feb 3, 2015
Materials and methods for conjugating a water soluble fatty acid derivative to a protein
SIEKMANN JUERGEN15 citations80
BAXTER INT
2 patentsUS8623612B2Jan 7, 2014
Method for testing treatment of ADAMTS13 deficiency
BAXTER INT10 citations92
US9110085B2Aug 18, 2015
Methods of testing effectiveness of a treatment for thromobotic thrombocytopenic purpura by measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor
BAXTER INT8 citations83
VARADI KATALIN
2 patentsUS8415114B2Apr 9, 2013
Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof
VARADI KATALIN8 citations81
US9274122B2Mar 1, 2016
Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation)
VARADI KATALIN0 citations48